Edition:
United States

Galena Biopharma Inc (GALE.OQ)

GALE.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
12:05pm EDT
Change (% chg)

$0.00 (+0.45%)
Prev Close
$0.56
Open
$0.56
Day's High
$0.57
Day's Low
$0.55
Volume
43,876
Avg. Vol
298,533
52-wk High
$49.80
52-wk Low
$0.52

Latest Key Developments (Source: Significant Developments)

Galena Biopharma Q1 loss per share $0.45
Wednesday, 10 May 2017 04:30pm EDT 

May 10 (Reuters) - Galena Biopharma Inc ::Galena Biopharma reports first quarter 2017 financial results.Q1 loss per share $0.09 from continuing operations.Q1 loss per share $0.45.  Full Article

Galena Biopharma presents positive interim safety data on NeuVax clinical trial
Tuesday, 4 Apr 2017 07:05am EDT 

Galena Biopharma Inc : Galena Biopharma presents positive interim safety data on the neuva (nelipepimut-s) clinical trial in combination with trastuzumab in high-risk HER2 3+ patients at the AACR annual meeting 2017 .Galena Biopharma Inc says in trial, there were no significant clinicopathologic differences between groups.  Full Article

Galena presents positive early-stage data on GALE-301
Friday, 17 Mar 2017 07:05am EDT 

Galena Biopharma Inc : Galena biopharma presents positive final gale-301 (e39) phase 1/2a clinical trial data . Galena biopharma - patients with primary disease who received 1000mcg dose appear to maintain a statistically significant benefit while those with recurrent disease were not .Galena biopharma inc - final data from early stage clinical trial demonstrates that gale-301 is well tolerated.  Full Article

Galena Biopharma evaluates strategic alternatives
Wednesday, 15 Mar 2017 04:15pm EDT 

Galena Biopharma Inc : Galena Biopharma reports fourth quarter and year end 2016 financial results and provides a corporate update . Q4 loss per share $0.49 .Galena Biopharma - working closely with advisors to evaluate strategic alternatives, including monetizing assets, sale of co, a business combination.  Full Article

Galena Biopharma engages Canaccord Genuity to advise on strategic alternatives
Thursday, 9 Mar 2017 07:05am EST 

Galena Biopharma Inc : Galena biopharma engages Canaccord Genuity to advise on strategic alternatives . Galena biopharma - potential strategic alternatives may include a sale of company, a business combination, a merger or reverse merger with another party .Galena biopharma - potential strategic alternatives may include continuing to advance clinical programs as stand-alone entity, disposition of assets.  Full Article

CVI Investments reports 9.3 pct passive stake in Galena Biopharma
Friday, 17 Feb 2017 08:56am EST 

Galena Biopharma Inc :CVI Investmentsreports 9.3 percent passive stake in Galena Biopharma Inc as of feb 8 - SEC filing.  Full Article

Galena Biopharma announces pricing of public offering of common stock and warrants
Wednesday, 8 Feb 2017 08:30am EST 

Galena Biopharma Inc : Galena Biopharma announces pricing of public offering of common stock and warrants . Galena Biopharma Inc- pricing of an underwritten public offering of units with anticipated gross proceeds of $17 mln .Galena Biopharma - offering each unit that consists of 1 full share of stock, warrant to purchase 1 share of common stock, is priced at $1.00 per unit.  Full Article

Galena Biopharma announces proposed public offering of common stock and warrants
Tuesday, 7 Feb 2017 04:10pm EST 

Galena Biopharma Inc :Galena Biopharma announces proposed public offering of common stock and warrants.  Full Article

Galena biopharma reports positive outcome from the data safety monitoring board on the two Neuvax trials
Monday, 6 Feb 2017 07:05am EST 

Galena Biopharma Inc : Galena Biopharma reports positive outcome from the data safety monitoring board on the two neuvax (nelipepimut-s) clinical trials in combination with trastuzumab . Interim efficacy analysis for low-to-intermediate (her2 1+/2+) trial now expected by end of 2017 . Says interim efficacy analysis for low-to-intermediate (her2 1+/2+) trial now expected by end of 2017 . Both combination trials are deemed not futile and data safety monitoring board recommends that both trials continue . DSMB expects to perform interim efficacy analysis near end of 2017 . Says data safety monitoring board reported that there are no safety concerns with either trial and neither was found to be futile .Phase 2 trial showed agent is well tolerated with no increased cardiotoxicity associated with giving Neuvax with Trastuzumab.  Full Article

Galena biopharma announces the resignation of its President and CEO and the evaluation of strategic alternatives
Tuesday, 31 Jan 2017 05:00pm EST 

Galena Biopharma Inc : Galena Biopharma announces the resignation of its President and Chief Executive Officer and the evaluation of strategic alternatives . Galena Biopharma Inc - Board of directors expects to appoint an interim Chief Executive Officer in next couple weeks. . Galena Biopharma announces the resignation of its president and Chief Executive Officer and the evaluation of strategic alternatives . Says company is evaluating appropriate time to commence GALE-401 trial and anticipates making a definitive determination in second half of 2017 . Galena Biopharma Inc - Process of engaging an independent advisory firm to evaluate strategic alternatives for company . Galena Biopharma Inc- Potential strategic alternatives that may be explored or evaluated as part of this review include a sale of company .Galena Biopharma Inc- Potential strategic alternatives as part of this review include continuing to advance clinical programs as a stand-alone entity.  Full Article

More From Around the Web

BRIEF-RXI Pharma, PCI Biotech extend preclinical research collaboration

* RXI Pharmaceuticals -co and PCI Biotech announced that they are extending their preclinical research collaboration initiated April 7, 2015 Source text for Eikon: Further company coverage: